Ruxolitinib for myelofibrosis-An update of its clinical effects.
Clinical Lymphoma, Myeloma and Leukemia.
Times cited: 14
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
New England Journal of Medicine.
Times cited: 981
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Journal of Clinical Oncology.
Times cited: 166
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Times cited: 258